Cleared Traditional

K200207 - xPORT S Lens Fragmentation System

K200207 is an FDA 510(k) clearance for xPORT S Lens Fragmentation System, manufactured by Carl Zeiss Meditec Cataract Technology, Inc.. The device is a Class 2 Ophthalmic device with product code HQC cleared through the Traditional 510(k) pathway after a 261-day FDA review.

K200207 · Carl Zeiss Meditec Cataract Technology, Inc. · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2020
Decision
261d
Days
Class 2
Risk

K200207 is an FDA 510(k) clearance for the xPORT S Lens Fragmentation System. Classified as Unit, Phacofragmentation (product code HQC), Class II - Special Controls.

Submitted by Carl Zeiss Meditec Cataract Technology, Inc. (Reno, US). The FDA issued a Cleared decision on October 15, 2020 after a review of 261 days - an extended review cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.4670 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Ophthalmic review framework, consistent with the majority of Class II 510(k) submissions.

View all Carl Zeiss Meditec Cataract Technology, Inc. devices

FDA 510(k) Submission Details - K200207

510(k) Number K200207 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 28, 2020
Decision Date October 15, 2020
Days to Decision 261 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary Statement
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
151d slower than avg
Panel avg: 110d · This submission: 261d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

HQC Device Classification - Class 2, Special Controls

Product Code HQC Unit, Phacofragmentation
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 886.4670
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Ophthalmic devices follow this clearance model.

Regulatory Peers - HQC Unit, Phacofragmentation

All 121
Devices cleared under the same product code (HQC) and FDA review panel - the closest regulatory comparables to K200207.
EVA NEXUS Ophthalmic Surgical System
K213467 · D.O.R.C. Dutch Ophthalmic Research Center (International) · Jun 2022
QUATERA 700
K212241 · Carl Zeiss Meditec, AG · Apr 2022
VERITAS Phacoemulsification Console, VERITAS Advanced Fluidics Pack and Advanced Infusion Pack, VERITAS Swivel Handpiece, VERITAS Advanced Foot Pedal, VERITAS Remote Control
K203060 · Johnson & Johnson Surgical Vision, Inc. · Mar 2021
xPORT 304 (miCOR) System Lens Fragmentation System
K200584 · Carl Zeiss Meditec Cataract Technology, Inc. · Jul 2020
Visalis V500, Visalis S500
K193376 · Carl Zeiss Meditec, AG · Jun 2020
Phacoemulsification Needle (Tip) and Irrigation Sleeve
K192418 · Raico, LLC · May 2020